ABVC BioPharma, Inc. announced that each of the company and BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187 million, by third-party lender) (the Licensed Products). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. With this new licensing agreement in place, ABVC will continue to serve as the R&D partner of ForSeeCon to discover new pipelines for ophthalmic products.

From better vitreous substitutes to various eyecare products, platform remains dedicated to showcasing the best eyecare company can offer. ABVC will receive the first licensing payment of USD 30,000,000 (cash/shares) within 30 days after executing the agreement. ABVC is entitled to another milestone payment of $3,500,000 in cash after the first useful fundraise and royalties of 5% of net sales, up to $60,000,000, after the launch of the Licensed Product.

BioFirst is entitled to the same licensing fees and royalties as ABVC.